Provided is a nerve growth factor mutant, wherein the nerve growth factor mutant is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a nerve growth factor can alleviate side effects such as pain, falling within the field of biological pharmacy.

Provided is a nerve growth factor mutant, wherein the nerve growth factor mutant is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a nerve growth factor can alleviate side effects such as pain, falling within the field of biological pharmacy.

A method for manufacturing a proteoglycan-containing composition including: a freezing step for freezing a starting material, where raw cartilage derived from fish is used as the starting material; and a freeze-drying step for freeze-drying frozen articles obtained in the freezing step. The method may also include an extraction step for furthermore adding an aqueous solvent to the resultant freeze-dried articles to carry out extraction. Additionally, a method for manufacturing a proteoglycan-containing composition including a mincing step for forming a starting material into surimi, where raw cartilage derived from fish is used as the starting material; and an extraction step for adding an aqueous solvent to the surimi obtained in the mincing step to carry out extraction.

A gene combination capable of high-efficiency expression of rhNGF is provided to optimize gene expression regulation components of a recombinant human nerve growth factor. The gene combination enhances expression of rhNGF. As shown by experiments, the gene combination is capable of high-efficiency expression of a recombinant human nerve growth factor (rhNGF) with natural activity in a eukaryotic expression system.

A modified recombinant human nerve growth factor (modified rhNGF) is obtained from the reaction between a polymer of formula A and an rhNGF. The polymer of formula A is an N-disubstituted amino acetamino aldehyde derivative. Experimental results have shown that the modified rhNGF has a higher in vivo plasma concentration and a longer in vivo half-life than when the rhNGF is not modified or is modified by monomethoxy polyglycol, and that the modified rhNGF preserves the original activity of the unmodified rhNGF. Moreover, the method of preparing the modified rhNGF is low-cost, and the modified products are highly consistent.

##STR00001##

A modified recombinant human nerve growth factor (modified rhNGF) is obtained from the reaction between a polymer of formula A and an rhNGF. The polymer of formula A is an N-disubstituted amino acetamino aldehyde derivative. Experimental results have shown that the modified rhNGF has a higher in vivo plasma concentration and a longer in vivo half-life than when the rhNGF is not modified or is modified by monomethoxy polyglycol, and that the modified rhNGF preserves the original activity of the unmodified rhNGF. Moreover, the method of preparing the modified rhNGF is low-cost, and the modified products are highly consistent.

##STR00001##

The present invention provides a non-natural polypeptide for the treatment or prevention of skin disorders in a mammal. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypeptide is provided at high purity.

The present invention provides a non-natural polypeptide for the treatment or prevention of skin disorders in a mammal. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypeptide is provided at high purity.

The present disclosure relates to the field of unconventional neurotrophic factors and to the field of treating degenerative, chronic or progressive diseases and disorders, and monogenic hereditary diseases having ER stress as a pathogenic compound. More particularly the disclosure relates to modified peptides, particularly retro-inverso peptides. The disclosure also relates to pharmaceutical compositions comprising said peptides. Further, the disclosure also relates to said peptides, and pharmaceutical compositions for use as a medicament and in the treatment of degenerative, chronic or progressive diseases and disorders, and monogenic hereditary diseases having ER stress as a pathogenic compound as well as to methods for treating said diseases and disorders.

The present disclosure relates to the field of unconventional neurotrophic factors and to the field of treating degenerative, chronic or progressive diseases and disorders, and monogenic hereditary diseases having ER stress as a pathogenic compound. More particularly the disclosure relates to modified peptides, particularly retro-inverso peptides. The disclosure also relates to pharmaceutical compositions comprising said peptides. Further, the disclosure also relates to said peptides, and pharmaceutical compositions for use as a medicament and in the treatment of degenerative, chronic or progressive diseases and disorders, and monogenic hereditary diseases having ER stress as a pathogenic compound as well as to methods for treating said diseases and disorders.